Prestige Consumer Healthcare Inc has a consensus price target of $70.83, established from looking at the 13 latest analyst ratings. The last 3 analyst ratings were released from DA Davidson, DA Davidson, and RBC Capital on June 26, 2023, May 8, 2023, and March 17, 2023. With an average price target of $74.67 between DA Davidson, DA Davidson, and RBC Capital, there's an implied 5.03% upside for Prestige Consumer Healthcare Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
06/26/2023 | PBH | Buy Now | Prestige Consumer | $71.09 | -15.6% | DA Davidson | Linda Bolton Weiser | → $60 | Reiterates | Neutral → Neutral | Get Alert |
05/08/2023 | PBH | Buy Now | Prestige Consumer | $71.09 | -15.6% | DA Davidson | Linda Bolton Weiser | → $60 | Reiterates | → Neutral | Get Alert |
03/17/2023 | PBH | Buy Now | Prestige Consumer | $71.09 | 46.29% | RBC Capital | Sabahat Khan | $107 → $104 | Maintains | Sector Perform | Get Alert |
02/17/2023 | PBH | Buy Now | Prestige Consumer | $71.09 | -0.13% | Oppenheimer | Rupesh Parikh | $72 → $71 | Maintains | Outperform | Get Alert |
01/13/2023 | PBH | Buy Now | Prestige Consumer | $71.09 | 1.28% | Oppenheimer | Rupesh Parikh | $63 → $72 | Maintains | Outperform | Get Alert |
11/17/2022 | PBH | Buy Now | Prestige Consumer | $71.09 | -0.13% | Canaccord Genuity | Susan Anderson | → $71 | Initiates | → Buy | Get Alert |
05/10/2022 | PBH | Buy Now | Prestige Consumer | $71.09 | -1.53% | Jefferies | Stephanie Wissink | $65 → $70 | Upgrade | Hold → Buy | Get Alert |
05/09/2022 | PBH | Buy Now | Prestige Consumer | $71.09 | -11.38% | Oppenheimer | Rupesh Parikh | → $63 | Upgrade | Perform → Outperform | Get Alert |
05/09/2022 | PBH | Buy Now | Prestige Consumer | $71.09 | -15.6% | DA Davidson | Linda Bolton Weiser | $63 → $60 | Maintains | Neutral | Get Alert |
11/15/2021 | PBH | Buy Now | Prestige Consumer | $71.09 | -11.38% | DA Davidson | Linda Bolton Weiser | — | Maintains | Neutral | Get Alert |
08/06/2021 | PBH | Buy Now | Prestige Consumer | $71.09 | -14.19% | DA Davidson | Linda Bolton Weiser | — | Maintains | Neutral | Get Alert |
05/28/2021 | PBH | Buy Now | Prestige Consumer | $71.09 | -26.85% | DA Davidson | Linda Bolton Weiser | — | Maintains | Neutral | Get Alert |
05/10/2021 | PBH | Buy Now | Prestige Consumer | $71.09 | -31.07% | DA Davidson | — | — | Maintains | Neutral | Get Alert |
The latest price target for Prestige Consumer (NYSE: PBH) was reported by DA Davidson on June 26, 2023. The analyst firm set a price target for $60.00 expecting PBH to fall to within 12 months (a possible -15.60% downside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Prestige Consumer (NYSE: PBH) was provided by DA Davidson, and Prestige Consumer reiterated their neutral rating.
The last upgrade for Prestige Consumer Healthcare Inc happened on May 10, 2022 when Jefferies raised their price target to $70. Jefferies previously had a hold for Prestige Consumer Healthcare Inc.
There is no last downgrade for Prestige Consumer.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prestige Consumer, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prestige Consumer was filed on June 26, 2023 so you should expect the next rating to be made available sometime around June 26, 2024.
While ratings are subjective and will change, the latest Prestige Consumer (PBH) rating was a reiterated with a price target of $0.00 to $60.00. The current price Prestige Consumer (PBH) is trading at is $71.09, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.